All In Biotech

Drug Trial Radar · NCT02755064

Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jun 2010

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Adil BharuchaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With this study, the investigators hoped to learn if the rate at which food empties from the stomach affects blood sugar values. Using data from this study, we hope to improve our ability to control blood sugars in individuals with type 1 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Erythromycin lactobionateDrug

    In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.

  • Placebo IVDrug

    In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.

  • [13C]-SpirulinaDrug

    The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.

  • Erythromycin Ethylsuccinate SuspensionDrug

    In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.

  • Placebo SuspensionDrug

    In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relationship between gastric emptying and glycemiaTime frame: 11 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.